DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
12 Setembro 2023 - 9:13AM
Business Wire
Dr. Shah Has Spent Over Two Decades Leading
Biological Development Teams at Biotechnology Companies and Has
Deep Expertise in Protein Development and Manufacturing
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage
biopharmaceutical company focused on developing novel treatments
for neurological disorders and cardio-renal disease, announced
today the appointment of Ambarish Shah, Ph.D. as Chief Technology
Officer. Dr. Shah will lead the development of DiaMedica’s
manufacturing operations for the late-stage drug candidate DM199.
Since May 2023, Dr. Shah has been advising DiaMedica as it worked
through the final resolution of the clinical hold on the
investigational new drug application for its ReMEDy2 clinical trial
of DM199 in acute ischemic stroke patients.
Dr. Shah has over 25 years of experience in advancing
biopharmaceuticals from early stage to commercialization. He was
previously the Vice President and Head of Global Vaccines
Development at CSL Seqirus where he was accountable for end-to-end
chemistry, manufacturing and control (CMC) in the development of
vaccines. Prior to that position, he was Executive Director, Head
of Drug Product Development at Bristol-Myers Squib (formerly
Celgene). His prior experience comprised increasingly impactful
roles at AstraZeneca (formerly MedImmune), GlaxoSmithKline
(formerly Human Genome Sciences) and Pfizer (formerly Wyeth).
“Ambarish has made invaluable contributions to the advancement
of more than 50 biologics across various stages of development,
solidifying a distinguished track record in the establishment of
cutting-edge scientific capabilities,” commented Rick Pauls,
DiaMedica’s President and Chief Executive Officer.
“I am delighted to join DiaMedica at this pivotal time in the
Company’s advancement,” said Dr. Shah. “Over the past four months,
I’ve had the chance to fully understand the DM199 development
program and get to know the team at DiaMedica and their unwavering
commitment to bring this innovative technology to stroke
patients.”
Dr. Shah received his Bachelor of Pharmacy degree from Mumbai
University, India and his Master of Science in Pharmaceutical
Sciences from Duquesne University, Pittsburgh, PA. He obtained his
doctorate in Pharmaceutical Sciences from Mercer University,
Atlanta, Georgia with a focus on Drug Delivery.
About DM199
DM199 is a recombinant (synthetic) form of human tissue
kallikrein-1 (KLK1). KLK1 is a serine protease (protein) that plays
an important role in the regulation of diverse physiological
processes including blood flow, inflammation, fibrosis, oxidative
stress and neurogenesis via a molecular mechanism that increases
production of nitric oxide and prostaglandin. KLK1 deficiency may
play a role in multiple vascular and fibrotic diseases such as
stroke, chronic kidney disease, retinopathy, vascular dementia, and
resistant hypertension where current treatment options are limited
or ineffective. DiaMedica is the first company to have developed
and clinically studied a recombinant form of the KLK1 protein. The
KLK1 protein, produced from the pancreas of pigs and human urine,
has been used to treat patients in Japan, China and South Korea for
decades. DM199 is currently being studied in patients with acute
ischemic stroke (AIS). In September 2021, the FDA granted Fast
Track Designation to DM199 for the treatment of AIS.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company committed to improving the lives of
people suffering from serious diseases with a focus on acute
ischemic stroke. DiaMedica’s lead candidate DM199 is the first
pharmaceutically active recombinant form of the KLK1 protein, an
established therapeutic modality in Asia for the treatment of acute
ischemic stroke and other vascular diseases. For more information
visit the Company’s website at www.diamedica.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230912625342/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118
skellen@diamedica.com
Paul Papi Corporate Communications Phone: (508) 444-6790
ppapi@diamedica.com
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
